Elevance Health has projected a profit for 2024 that exceeds expectations, citing higher premiums in its commercial insurance segment that effectively managed medical costs during the fourth quarter. This announcement led to a nearly 4% surge in the company’s stock during early morning trade.
The optimistic forecast from Elevance Health follows a period of turbulence in the health insurance sector, triggered by a warning issued by rival Humana last week. Humana expressed concerns that an uptick in demand for medical care among older adults could potentially impact its 2024 outlook, leading to a decline in shares across the health insurance industry.
In response to the positive outlook from Elevance Health, shares of competitors such as CVS and Cigna experienced a notable uptick, rising over 1% during morning trading.
Despite an increase in demand for certain procedures, particularly knee and hip replacements among older adults in the fourth quarter, Elevance Health reported that overall expenses remained in line with its previous expectations. Mark Kaye, the Chief Financial Officer, attributed this stability to the effective management of costs.
The company’s optimistic 2024 profit forecast is driven by expectations that medical expenses will remain steady throughout the year. Additionally, the higher pricing of its commercial health insurance plans is contributing to the positive outlook, as noted by Stephens analyst Scott Fidel.
In contrast to industry counterparts such as Humana and UnitedHealth (UNH.N), both of which signaled a surge in medical procedures during the fourth quarter, Elevance Health maintains a comparatively lesser presence in the Medicare Advantage (MA) plans market, designed for individuals aged 65 and above. Fidel suggests that this lower exposure to MA plans likely played a crucial role in Elevance’s ability to control costs effectively.
Examining the health insurer’s benefit expense ratio, which represents the percentage of premiums allocated to medical care, the fourth quarter figure stood at 89.2%. This figure was slightly below the analysts’ average estimate of 89.4%, according to data from the London Stock Exchange Group.
The positive market response to Elevance Health’s outlook was evident as the company’s shares, formerly known as Anthem, reached a nine-month high of $489.5. This upward trajectory reflects investor confidence in the company’s strategic management of costs and its ability to navigate the evolving landscape of the health insurance sector.
As the industry grapples with various challenges, including changes in demand for medical services and potential impacts on outlooks, Elevance Health’s performance and outlook provide a nuanced perspective on how effective management and strategic positioning can contribute to financial resilience and market confidence. The company’s focus on commercial health insurance plans and its approach to Medicare Advantage plans underscore the complexity of the sector and the importance of a tailored strategy to address specific market dynamics.
